Update on Alzheimer drugs ( XXXX ).

@entity1 @entity390 @entity1294 @entity294 @entity73 @entity195 @entity8124
BACKGROUND: Several clinical trials have been conducted over a period of many years reporting the benefits of @entity8124 for @entity195 ( @entity195 ) @entity1 . REVIEW SUMMARY: Randomized, double-blind, placebo-controlled stud-ies of 3-6 months' duration have demonstrated significant benefits for 5mg/D and 10 mg/D of @entity8124 compared with placebo. The results include benefits for cognition, activities of daily living, and abnormal behaviors associated with @entity195 . The benefits are independently detectable by clinicians based upon direct @entity1 assessment with input from a caregiver. Populations studied include mild-to-moderate @entity195 @entity1 , moderate-to-severe @entity195 @entity1 , nursing home @entity1 , and outpatients. Open label studies that took place after the double-blind phase and 1-year double-blind, placebo-controlled trials demonstrated that benefits persist for more than a year. Adverse event (AE) profiles, generated in studies that used a 1-week forced dose titration, show a low incidence of primarily cholinegic AEs such as @entity390 and @entity294 . There are no significant laboratory AEs or drug interactions. Recent studies have assessed the benefits of @entity8124 inpatients with @entity1294 , mild @entity73 , and other @entity73 . CONCLUSIONS: @entity8124 benefits @entity195 @entity1 by improving, stabilizing, or retarding decline of the cognitive, functional, and possibly behavioral features of the disease. The duration of benefits is not known but extends beyond 1 year. The drug is safe and well tolerated.
